Physician profile
Daniel Thomas Sandlin
NPI 1770993792
$10,208.95
in general payments reported to CMS, 2019-2025
42 companies · $1,002 in 2025
The $1,002 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,564 · 2020: $726 · 2021: $1,448 · 2022: $1,049 · 2023: $1,281 · 2024: $1,139 · 2025: $1,002.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,855 · Education: $568.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,854.97 |
| Education | $567.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,189.66 | 2019-2025 | Proclaim, Prodigy, Octrode |
| Vertiflex, INC. | $1,407.43 | 2019 | |
| Boston Scientific Corporation | $1,103.19 | 2020-2025 | Wavewriter Alpha Prime 16, Fixate, Superion Indirect Decompression System |
| Medtronic, INC. | $691.69 | 2021-2025 | Intellis Adaptivestim, Accurian |
| Abbvie INC. | $526.46 | 2021-2025 | Ubrelvy, Botox, Qulipta |
| Curonix LLC | $513.52 | 2023-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Collegium Pharmaceutical, INC. | $332.31 | 2019-2025 | Xtampza, Belbuca |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $253.68 | 2019-2025 | Relistor |
| Nevro Corp. | $239.68 | 2019-2024 | Senza |
| Globus Medical, INC. | $163.57 | 2025 | Senza |
| Painteq LLC | $161.11 | 2021-2022 | |
| Upsher-Smith Laboratories LLC | $139.96 | 2019-2022 | |
| Amgen INC. | $133.22 | 2020-2022 | |
| Ibsa Pharma INC. | $130.51 | 2021-2025 | Tirosint, Licart, Tirosint |
| Hikma Pharmaceuticals USA | $124.48 | 2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Sandlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.